Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Victoria Carter

Physician Assistant Birmingham, AL Physician Assistant

NPI 1871204313 CMS profile 11435756

1201 11Th Ave S, Birmingham, AL 35205

Open in the dashboard

General payments

$7,579

324 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Victoria Carter of Birmingham, AL is reported in the CMS Open Payments database as having received $7,579 across 324 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $986 41
2024 General $2,983 129
2023 General $3,610 154

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Victoria Carter
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Victoria Carter were reported at $986. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Victoria Carter Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $3,610 $167 $52–$557 $160
2024 $2,983 $178 $55–$600 $164
2025 $986 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $1,519 47 payments
  2. GlaxoSmithKline, LLC. $786 47 payments
  3. Regeneron Healthcare Solutions, Inc. $764 27 payments
  4. United Therapeutics Corporation $439 19 payments
  5. Actelion Pharmaceuticals US, Inc. $372 14 payments
  6. Mallinckrodt Hospital Products Inc. $365 11 payments
  7. Amgen Inc. $363 27 payments
  8. Genzyme Corporation $352 16 payments
  9. Axsome Therapeutics, Inc. $348 11 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $329 15 payments
  11. Other $1,941 90 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $7,430 322 payments
  2. Education $149 2 payments
Products named General payments · program years 2023–2025
  1. TEZSPIRE Respiratory $851 16 payments
  2. FASENRA $753 15 payments
  3. DUPIXENT Inflammation And Immunology $709 25 payments
  4. AIRSUPRA $685 14 payments
  5. DUPIXENT Immunology $402 17 payments
  6. NUCALA $390 24 payments
  7. BREZTRI $367 6 payments
  8. OPSUMIT $351 13 payments
  9. Sunosi $348 11 payments
  10. TEZSPIRE Inflammation $338 26 payments
  11. Other $3,848 183 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

2,565

Median for Physician Assistant: 241

Drug cost

$1,234,001

Median for Physician Assistant: $4,110

Branded share of claims

70.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 481 $369,444
Uptravi Selexipag Brand 11 $247,033
Ofev Nintedanib Esylate Brand 12 $159,074
Nucala Mepolizumab Brand 14 $143,119
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 80 $66,696
Symbicort Budesonide/Formoterol Fumarate Brand 133 $46,437
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 83 $38,421
Breo Ellipta Fluticasone/Vilanterol Brand 66 $36,403
Spiriva Respimat Tiotropium Bromide Brand 43 $32,286
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 44 $28,726

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$23,721

Of which drugs: $354

Medicare patients

254

Average age 74

Services billed

837

149 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
COPD 52%
Chronic kidney disease 40%
Diabetes 37%
Ischemic heart disease 35%
Heart failure 31%
Depression 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 34 440 $321

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $533
  • GENZYME CORPORATION $149
$682 — —
TEZSPIRE
  • Amgen Inc. $176
  • AstraZeneca Pharmaceuticals LP $149
$326 — —
NUCALA
  • GlaxoSmithKline, LLC. $233
$233 14 —
TYVASO
  • United Therapeutics Corporation $212
$212 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $167
$167 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

324 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record